Michelle Prillo

Background

About Michelle Prillo

Seasoned Global Director of Project Delivery and Clinical Operations with over 20 years of experience in the pharmaceutical, biotechnology and contract research organization industry. Committed to building, leading, and motivating global clinical operations teams to exceed organizational goals for high-quality clinical trial delivery. Highly motivated, forward-thinking, results-focused leader and strategist dedicated to continuous improvement, efficiency and team building across functions, locations and cultures. 21 years of experience in the pharmaceutical industry, 16 years experience in Project/Portfolio/Program Management, 16 years experience in Vendor Management, 13 years experience in Oncology, and 9 years of CRO experience. Qualified in Phase I - IV trials, Global studies (North America, LATAM, EMEA, APAC), pediatric studies, registry studies, rescue studies, dose escalation, dose expansion, multi-cohort, basket studies, tumor agnostic studies, immunotherapy, CAR-T, cell and gene therapy, cancer vaccines, complex rare diseases, checkpoint cell therapy, combination therapy, orphan drugs, plasma derived products, radiopharmaceuticals, nuclear medicine, investigator initiated trials, and special access programs. Predominant therapeutic area experiences include Oncology, Hematology, Precision Medicine, Translational Research, Nuclear Medicine, Rare Disease, Pediatrics, Immunology, Neurology, Urology, Cardiovascular, Vaccines, Transplant and Respiratory. Specific indication experience includes Prostate cancer, Breast cancer, Colorectal Cancer, Ovarian Cancer, Solid tumors, Advanced solid malignancies, Brain Cancer, Liver Cancer, Systemic mastocytosis, Chronic lymphocytic leukemia, Small cell lymphocytic lymphoma, Non-Hodgkin lymphoma, Follicular lymphoma, Anaplastic large cell lymphoma, Peripheral T-cell lymphoma, Cutaneous T-Cell lymphoma, B-cell lymphoma, Waldenstroms macroglobulinemia, Squamous cell carcinoma, Non-small cell lung cancer, Glioblastoma multiforme, Mast cell leukemia, Mantle cell lymphoma, Acute Myelogenous Leukemia, Metastatic Gastrointestinal Epithelial Cancer, Immune Thrombocytopenia, Primary Immunodeficiency Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Neuroendocrine Tumors, Hemolytic Disease of the Fetus and Newborn, Benign Prostatic Hyperplasia, Heart Failure, Asthma, Transplant (liver, heart, kidney), DNA Cancer Vaccine.